Ps psychedelic as the possible mental health treatment are explored by the Trump administration
NEWNow you can listen to News articles!
The Trump administration has expressed interest in exploring psychedelics for their potential in the treatment of PTSD and other weakening mental health problems, they have shared several officials.
“The department shares the objective of ensuring that all Americans, especially veterans of our nation, have access to safe and effective treatments for conditions such as PTSP, addiction and depression,” a spokesman for the Department of Health and Human Services of the United States (HHS), directed by Sec. Robert J. Kennedy Jr., said in a statement provided to News Digital.
“Secretary Kennedy undertakes to apply a rigorous science based on evidence to research efforts aimed at addressing these serious health challenges.”
The FDA approves the first AI tool to predict the risk of breast cancer
In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and Psilocybin (“magical fungi”) to treat mental health disorders.
The MDMA is not approved for clinical use by the Food and Medicines Administration of the United States (FDA), but can be studied in clinical environments.
The psychedelic research has obtained the support of the Trump administration to treat PTSD and mental health conditions. (Istock)
Psilocybin appears as a substance of schedule I under the law of controlled substances, which means that it has a high potential for abuse, [is not] Currently accepted for medical use in treatment in the United States and [has] Lack of safety accepted for use under medical supervision. “
However, psilocybin assisted therapy is legal in Oregon, Colorado and New Mexico.
‘Show promise’
Psychodelic medications are “showing a true promise,” according to Dr. Luke Twelves, general practitioner and vice president of Medical for Lindus Health in London.
Clinical trials have found such safe and effective treatments for patients fighting serious mental health problems, according to Twelves.
Common supplements and medications can cause liver damage, according to studies
“Take the psilocybin, for example, it is demonstrating notable results for severe depression that has not responded to other medications,” Digital News told News. “MDMA shows similar advances for PTSD treatment.”
Clinical trials are also investigating how psychedelics could help with anxiety at the end of life, addiction, eating disorders, chronic pain and OCD, he added.
In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and Psilocibin to treat mental health disorders. (Istock)
The researchers have faced challenges in terms of appropriate regulatory obstacles and appropriate placebo controls, Twelves said.
“Since these treatments could be transformed [the] The life of people who suffer conditions in which nothing has worked effectively, is crucial that we complete this research properly, “he said.” The goal is to bring safe and proven psychedelic therapies to patients who need them most. “
Potential for veterans
At the May 1 Cabinet meeting of President Trump, the secretary of the Department of Veterans Affairs, Doug Collins, said that “we are opening the possibility of a psychedelic treatment.”
The retired sergeant from the Jonathan Lubecki army recently told Alexandria Hoff of News that MDMA stopped his PTSD while participating in a clinical trial.
The VA is now opening to the possibility of a psychedelic treatment to promote the health of veterans. (Istock)
“[I] I took my first dose of MDMA. I only took it three times as part of the clinical trial, I have not taken it since then and I have not found the need to take it since then, because I have not had PTSD, “he said.
Peter Kasperoowicz, press secretary of the Department of Veterans Affairs, told News Digital that the department is safely exploring all the roads that promote the health of veterans.
Falujah veterinarian converts the medal of heroism into a healing mission for warriors with the service dog program
“Preliminary findings have produced positive results in psychedelic therapies to treat mental health conditions,” he said.
The VA currently executes 11 clinical trials in several phases, with a total of about 800 veterans that are expected to participate.
Click here to get the News application
“The objective of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post -traumatic stress disorder, treatment resistant depressive disorder, major depressive disorder, other mental health conditions,” Kasperoowicz said.
Psilocybin is a drug from Annex I under the Law of Controlled Substances, but psilocybin assisted therapy is legal in Oregon, Colorado and New Mexico. (Istock)
A MDMA study published in the January 2025 edition of the American Journal of Psychiatry found that the substance is “different from classic psychedelics.”
The study pointed out: “MDMA allows the individual to maintain intact functioning of the ego and a greater degree of cognitive and perceptual lucidity while experiencing an altered prosocial consciousness that facilitates deeply emotional therapeutic advances.”
Click here to register in our health newsletter
The researchers concluded that MDMA showed “improved confidence, empathy, self -pity levels and a” tolerance window “” that lacks traditional psychotherapy.
The VA currently has 11 psychedelic clinical trials in several phases. (Istock)
Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told News Digital that “the moment is now to address the mental health crisis.”
He said it is “rewarding” that administration officials value the potential benefits of investigating alternative mental health treatments.
“Now is the time to address the mental health crisis.”
Currently, Cybin is in phase 3 of a CYB003 study, a type of psilocybin that has been given the designation of innovative therapy by FDA as an additional treatment for major depressive disorder (MDD).
“In the study of Phase 2 MDD, Cybin completed, the long -term efficacy results showed that 71% of the participants were in remission of depression, and 100% of the participants responded to the treatment at 12 months after only two doses of 16 mg of CYB003,” Drysdale said.
Risks and precautions
Dr. Marc Siegel, Clinical Professor of Medicine at the Nyu Langone Medical Center and Senior Medical Analyst of News, previously interviewed two of the country’s main researchers about psychedelics: Dr. Rachel Yehud NYYU PTSD PTSD.
“There is a great inconvenience in terms of unregulated recreational uses.”
“They agree that there is a therapeutic potential if studied with great care under a very strict medical guide, but there is a great inconvenience in terms of unregulated recreational uses,” Siegel told News Digital at that time.
Experts emphasize the importance of administering psychedelic in a safe environment when treating mental health conditions. (Istock)
“Both doctors see a probable therapeutic value for psychedelics if medical experts carefully manage it,” Siegel added.
Ryan Moss, director of Filament Health Sciences, a company for the development of natural psychedelic medications of the clinical stage in Canada, emphasized that it is important to administer psychedelics in a safe environment when treating mental health conditions.
For more health articles, visit www.Newsnews.com/health
“Psychedelic experiences can sometimes present anxiety, hallucinations and paranoia,” Moss told News Digital. “Some patients who use traditional psychedelic have informed having experienced adverse cardiovascular events during clinical trials.”
To mitigate these risks, the participants of the clinical trials recommended by MOSS receive exhaustive preparation and monitoring of trained professionals during the sessions.
Melissa Rudy and Angelica Stabile, both of News Digital, contributed reports.